M
Michael W. Weiner
Researcher at University of California, San Francisco
Publications - 146
Citations - 30280
Michael W. Weiner is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Alzheimer's disease & Alzheimer's Disease Neuroimaging Initiative. The author has an hindex of 64, co-authored 146 publications receiving 25564 citations. Previous affiliations of Michael W. Weiner include University of California, Berkeley & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack,David S. Knopman,William J. Jagust,Leslie M. Shaw,Paul S. Aisen,Michael W. Weiner,Ronald C. Petersen,John Q. Trojanowski +7 more
TL;DR: This work proposes a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegnerative biomarker become abnormal later, and correlate with clinical symptom severity.
Journal ArticleDOI
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
Clifford R. Jack,Matt A. Bernstein,Nick C. Fox,Paul M. Thompson,Gene E. Alexander,Danielle J Harvey,Bret J. Borowski,Paula J. Britson,Jennifer L. Whitwell,Chadwick P. Ward,Anders M. Dale,Joel P. Felmlee,Jeffrey L. Gunter,Derek L. G. Hill,Ronald J. Killiany,Norbert Schuff,Sabrina Fox-Bosetti,Chen Lin,Colin Studholme,Charles DeCarli,Gunnar Krueger,Heidi A. Ward,Gregory J. Metzger,Katherine T. Scott,Richard Philip Mallozzi,Daniel J. Blezek,Joshua Levy,Josef Phillip Debbins,Adam S. Fleisher,Marilyn S. Albert,Robert C. Green,George Bartzokis,Gary H. Glover,John P. Mugler,Michael W. Weiner +34 more
TL;DR: The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom‐based monitoring of all scanners could be used as a model for other multisite trials.
Journal ArticleDOI
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
Clifford R. Jack,David S. Knopman,William J. Jagust,Ronald C. Petersen,Michael W. Weiner,Paul S. Aisen,Leslie M. Shaw,Prashanthi Vemuri,Heather J. Wiste,Stephen D. Weigand,Timothy G. Lesnick,Vernon S. Pankratz,Michael C. Donohue,John Q. Trojanowski +13 more
TL;DR: In this article, a model of the major biomarkers of Alzheimer's disease (AD) was proposed and the authors described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clinical symptoms.
Journal ArticleDOI
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.
Ronald C. Petersen,Paul S. Aisen,Laurel A. Beckett,Michael C. Donohue,Anthony Gamst,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski,Michael W. Weiner +11 more
TL;DR: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics and the CSF measures heralded progression of clinical measures over 12 months.
Journal ArticleDOI
Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Susanne G. Mueller,Susanne G. Mueller,Michael W. Weiner,Michael W. Weiner,Leon J. Thal,Ronald C. Petersen,Clifford R. Jack,William J. Jagust,John Q. Trojanowski,Arthur W. Toga,Laurel A. Beckett +10 more
TL;DR: There is increasing evidence that a combination of currently existing neuroimaging and cerebrospinal fluid (CSF) and blood biomarkers can provide important complementary information and thus contribute to a more accurate and earlier diagnosis of AD.